AN2 Therapeutics, Inc. financial data

Symbol
ANTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1800 El Camino Real, Suite D, Menlo Park, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 875 % -58.8%
Debt-to-equity 10.5 % +24.4%
Return On Equity -54.7 % +6.49%
Return On Assets -49.5 % +8.23%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.8M shares +36.1%
Common Stock, Shares, Outstanding 29.8M shares +36%
Entity Public Float 109M USD -8.6%
Weighted Average Number of Shares Outstanding, Basic 29.8M shares +53%
Weighted Average Number of Shares Outstanding, Diluted 29.8M shares +53%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 56.2M USD +34.6%
General and Administrative Expense 15M USD +5.89%
Operating Income (Loss) -71.2M USD -25.1%
Net Income (Loss) Attributable to Parent -64.7M USD -19.1%
Earnings Per Share, Basic -2.18 USD/shares -148%
Earnings Per Share, Diluted -2.18 USD/shares -148%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.8M USD -34.4%
Cash, Cash Equivalents, and Short-term Investments 95.3M USD -16%
Assets, Current 107M USD +9.4%
Other Assets, Noncurrent 1.04M USD +44.9%
Assets 108M USD +9.66%
Accounts Payable, Current 1.89M USD -39.8%
Employee-related Liabilities, Current 1.84M USD +17.1%
Accrued Liabilities, Current 5.84M USD -9.31%
Liabilities, Current 14M USD +95.4%
Liabilities 10.1M USD -9.27%
Accumulated Other Comprehensive Income (Loss), Net of Tax -27K USD +77.3%
Retained Earnings (Accumulated Deficit) -186M USD -53.5%
Stockholders' Equity Attributable to Parent 98.4M USD +12.1%
Liabilities and Equity 108M USD +9.66%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.6M USD -51.7%
Net Cash Provided by (Used in) Financing Activities 349K USD +75.4%
Net Cash Provided by (Used in) Investing Activities 26.3M USD +141%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 29.8M shares +36%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.05M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.8M USD -34.4%
Deferred Tax Assets, Valuation Allowance 41.8M USD +92.1%
Deferred Tax Assets, Gross 41.8M USD +92.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64.6M USD -19.4%
Operating Lease, Liability, Current 13K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 20.8M USD +51.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.46M USD +86.6%
Additional Paid in Capital 284M USD +36%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 9.12M USD +37.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%